Travere Therapeutics Inc Ordinary Shares TVTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
-
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
-
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Travere Therapeutics to Participate at Upcoming Investor Conferences
-
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
-
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Trading Information
- Previous Close Price
- $48.91
- Day Range
- $48.98–52.72
- 52-Week Range
- $13.88–52.72
- Bid/Ask
- $51.60 / $54.50
- Shares Outstanding
- 92.99M
- Market Cap
- $4.84B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 140.70
- Price/Sales
- 8.22
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 497
- Website
- https://www.travere.com
Valuation
|
Metric
|
TVTX
|
|---|---|
Price/Earnings (Normalized) | 140.70 |
Price/Book Value | 45.79 |
Price/Sales | 8.22 |
Price/Cash Flow | 58.74 |
Price/Earnings
TVTX
Financial Strength
|
Metric
|
TVTX
|
|---|---|
Quick Ratio | 2.81 |
Current Ratio | 3.13 |
Interest Coverage | −4.53 |
Quick Ratio
TVTX
Profitability
|
Metric
|
TVTX
|
|---|---|
Return on Assets (Normalized) | 18.21% |
Return on Equity (Normalized) | 144.72% |
Return on Invested Capital (Normalized) | 23.62% |
Return on Assets
TVTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Bnzbgrlc | Mwtyt | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zqtyhpfmw | Rrkjpz | $64B | |||
| argenx SE ADR
ARGX
| Txgpsmhx | Qpfkl | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ggrckvz | Bcvmmkt | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Lcbbgvjcc | Hncfsl | $24B | |||
| BioNTech SE ADR
BNTX
| Tykxmyf | Tyqd | $23B | |||
| Incyte Corp
INCY
| Xqydwwwv | Jdljc | $22B | |||
| Moderna Inc
MRNA
| Qgxlxkdfs | Stbfs | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Grmtghq | Npmt | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Sxqxjfx | Mdg | $13B |
United States